GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical NewsObservational StudyObesity TreatmentGLP-1 Receptor AgonistTirzepatideEndocrinologyAdults with ObesityWeight Loss OutcomesPharmacogenomicsGenetic VariantsNausea and VomitingPersonalized Medicine Why...
GLP-1 Receptor Agonist Efficacy Reduced by Genetic Variants
GLP-1 Clinical Relevance #43Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic NewsObservational StudyType 2 DiabetesGLP-1 Receptor AgonistEndocrinologyAdults with DiabetesTreatment ResponseGenetic VariationPharmacogenomicsPrecision MedicineDrug EfficacyPersonalized Diabetes Care Why...
GLP-1 Receptor Agonist Response Tied to Genetic Variants
GLP-1 Clinical Relevance #51Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical NewsObservational StudyObesityGLP-1 Receptor AgonistEndocrinologyAdults with ObesityWeight Loss OutcomesGLP1R Gene MutationPharmacogenomicsDrug Response...
GLP-1 Receptor Agonist Weight Loss: Can Genes Predict Results?
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Genetic Predictors GLP-1Pharmacogenomics Weight LossGLP-1 Treatment ResponseGenetic Variants ObesityPersonalized GLP-1 Therapy Why...
Large Genetic Meta-Analysis Finds Endocannabinoid Pathway Variants Linked to Shared Psychiatric Risk
We identified nine SNPs significantly associated with a change in risk of having a mental disorder. The lead SNP was rs12805732 (Gene: Diacylglycerol Lipase Alpha; DAGLA). Four SNPs had substantial heterogeneity (I²>60%). DAGLA had the strongest association with disease risk in gene-based analysis.